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Abstract
Vascular calcification results from osteoblastic differentiation of vascular smooth muscle cells (VSMCs) and is a major risk
factor for cardiovascular events. Ghrelin is a newly discovered bioactive peptide that acts as a natural endogenous ligand of
the growth hormone secretagog receptor (GHSR). Several studies have identified the protective effects of ghrelin on the
cardiovascular system, however research on the effects and mechanisms of ghrelin on vascular calcification is still quite rare.
In this study, we determined the effect of ghrelin on osteoblastic differentiation of VSMCs and investigated the mechanism
involved using the two universally accepted calcifying models of calcifying vascular smooth muscle cells (CVSMCs) and beta-
glycerophosphate (beta-GP)-induced VSMCs. Our data demonstrated that ghrelin inhibits osteoblastic differentiation and
mineralization of VSMCs due to decreased alkaline phosphatase (ALP) activity, Runx2 expression, bone morphogenetic
protein-2 (BMP-2) expression and calcium content. Further study demonstrated that ghrelin exerted this suppression effect
via an extracellular signal-related kinase (ERK)-dependent pathway and that the suppression effect of ghrelin was time
dependent and dose dependent. Furthermore, inhibition of the growth hormone secretagog receptor (GHSR), the ghrelin
receptor, by siRNA significantly reversed the activation of ERK by ghrelin. In conclusion, our study suggests that ghrelin may
inhibit osteoblastic differentiation of VSMCs through the GHSR/ERK pathway.
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Introduction
Vascular calcification, previously viewed as a passive conse-
quence of aging [1], is often found in patients with atherosclerosis,
diabetes, renal failure and heart failure. It is also associated with
many clinical complications such as myocardial infarction,
impaired vascular tone, angioplasty dissection and poor surgical
outcome [2,3]. There is now a growing awareness that vascular
calcification is an active biologically regulated phenomenon that is
similar to bone formation [4,5]. This process includes the
expression of several osteoblast phenotype genes such as alkaline
phosphatase (ALP), core binding factor a1( cbfa1, Runx2),
osteocalcin and osteopontin, and requires the presence of the
bone mineral hydroxyl apatite and matrix vesicles [6]. Previous
studies have demonstrated the significant role of vascular smooth
muscle cells (VSMCs) in the active regulation of vascular
calcification by their acquisition of the phenotype of osteoblast-
like cells [7,8]. However, the mechanisms of this active process
have not been fully explained.
Ghrelin is a 28 amino acid acyl peptide that is esterified with
octanoic acid on Ser 3 and that belongs to the brain–gut peptide
family; it has been isolated from both human and rat stomach and
was first reported by Kojima in 1999 [9]. Subsequent studies have
identified that the stomach is the major source of circulating
ghrelin, but small amounts of ghrelin are also produced by other
organs such as the heart, lung or kidney [10,11]. Ghrelin has
multiple important physiological effects such as promotion of
growth hormone (GH) release from the pituitary, increase of food
intake, and regulation of energy homeostasis. In addition, recent
studies have demonstrated that ghrelin participates in many other
physiological processes that include circulation, inflammation,
glucose metabolism, cell proliferation, differentiation and apopto-
sis [12,13]. Furthermore, it has been shown that the endocrine
activities of ghrelin are mediated by the GH secretagog (GHS)
receptor (GHS-R). GHS-R is a G-protein-coupled receptor that is
mainly expressed in the pituitary gland and in the hypothalamus
and that has two subtypes: the fully functional GHSR-1a and the
biologically inactive GHSR-1b [14,15]. As stated earlier, ghrelin is
expressed by many organs and tissues especially those of
cardiovascular system [16]. In addition, it has been shown to play
a role in various cardiovascular activities such as increase in
myocardial contractility, decrease in mean arterial pressure,
vasodilatation, protection against myocardial infarction-induced
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attenuation of injury in the heart from ischemia/reperfusion.
Recent studies have demonstrated that ghrelin also plays an
important role in osteoblast proliferation and differentiation
[17,18]; these results suggest that ghrelin may exert paracrine/
autocrine effects in cardiovascular calcification. Recently, Li et al.
[19] reported that ghrelin could attenuate vascular calcification
through inhibition of osteoblastic differentiation of VSMCs;
however the mechanism of this inhibition is still not clear.
Calcifying VSMCs (CVSMCs) are a specific subpopulation of
VSMCs that can spontaneously express the osteoblast phenotype
gene and form calcification nodules [20]. Additionally, normal
primary VSMCs cultured with beta-glycerophosphate (beta-GP)
can be induced into the process of osteoblastic differentiation. In
the present study, both of these cell models were used to explore
the effect of ghrelin on osteoblastic differentiation of VSMCs. Our
data suggest that ghrelin may attenuate vascular calcification
through an extracellular signal-related kinase (ERK)-dependent
pathway.
Results
Ghrelin inhibited the osteoblastic differentiation and
mineralization of VSMCs
It is acknowledged that the process of vascular calcification is
similar that of bone mineralization, in which both ALP (the
phenotypic marker for osteoblastic differentiation) and Runx2 (the
transcription factor for osteoblastic differentiation and bone
formation) are up-regulated significantly [21]. The bone morpho-
genic proteins (BMPs) are important regulators of orthotopic bone
formation and two members of this group, BMP-2, and -4, are
associated frequently with vascular calcification [22]. In this study
ALP activity, and expression of BMP-2 and Runx2 were
determined to identify the inhibitory effects of ghrelin on
osteoblastic differentiation of VSMCs. Our data demonstrated
that treatment with ghrelin significantly inhibited ALP activity and
that the suppression was time dependent. In CVSMCs, significant
inhibition by ghrelin was first observed at 24 h and inhibition
peaked at 48 h. Details of the effects of ghrelin on ALP activity in
CVSMCs are shown in Figure 1A. In contrast, in VSMCs cultured
with beta-GP, significant inhibition by ghrelin was observed on
days 3 to 9 and inhibition peaked on day 6. Details of ALP activity
in VSMCs cultured with beta-GP are shown in Figure 2A.
The expression of Runx2 was determined by western blotting,
which was similar to that found for ALP in CVSMCs and VSMCs
cultured with beta-GP. Expression of Runx2 was inhibited
significantly after treatment with ghrelin for 48 h for CVSMCs
(Figure 1B and 1C) and 6 days for VSMCs (Figure 2B and 2C),
respectively.
BMP-2 expression was determined by real-time quantitative
polymerase chain reaction (qPCR). Our data showed that BMP-2
mRNA expression in CVSMCs and VSMCs was similar to that
for Runx2. Details are shown in Figure 1D and Figure 2D.
Figure 1E shows an entire plate of cells stained with Alizarin
Red S. Treatment of CVSMCs with ghrelin in culture for 12 days
significantly decreased the level of Alizarin Red S staining.
Similarly, the effects of ghrelin on calcium deposition in CVSMCs
were determined after incubation for 12 days and the data showed
that ghrelin markedly decreased calcium deposition in CVSMCs
(Figure 1F). In addition, the inhibitory effects of ghrelin on calcium
deposition in VSMCs cultured with beta-GP were also determined
after a 20-day incubation (Figure 2E) and the results showed the
same trends as those for CVSMCs.
Intracellular signaling mechanisms under stimulus of
ghrelin
Mitogen-activated protein kinases (MAPKs) play an essential
role in the control of cell differentiation and the MAPK signaling
pathway is known to be involved in osteoblastic differentiation of
VSMCs [4]. To confirm the involvement of MAPK signaling
molecules and explore the effects of ghrelin on osteoblastic
differentiation, the expression of three MAPK molecules, ERK, c-
Jun N-terminal kinases (JNK) and p38 MAPK (p38), were
determined in a calcification model and by ghrelin treatment.
Our data demonstrated that ERK was phosphorylated signifi-
cantly by ghrelin, but both JNK and p38 did not respond to
ghrelin stimulus but did respond to the positive control hydrogen
peroxide (H2O2). Specifically for CVSMCs, ERK activation
occurred at 5 min after the start of incubation and peaked at
30 min (Figure 3A and 3B), which suggested that the effects of
ghrelin on osteoblastic differentiation of CVSMCs may be
mediated by ERK. A range of concentrations of ghrelin
(1029 mol/L, 10
28 mol/L, 10
27 mol/L, and 10
26 mol/L) were
added to the CVSMCs culture for 30 min to determine their effect
on ERK activation. Our results showed that ghrelin at a
concentration that ranged from 10
28 mol/L to 10
26 mol/L
significantly activated ERK and that the activation was dose
dependent (Figure 3C), but that a concentration of 1029 mol/L
had no effect on ERK activation.
Ghrelin attenuated osteoblastic differentiation of
CVSMCs through the GHSR/ERK signaling pathway
Silencing of GHSR by siRNA and blockade of ERK
phosphorylation by its inhibitor, PD98059, were performed to
confirm that the inhibition of calcification of CVSMCs by ghrelin
was dependent on phosphorylation of ERK. Expression of both
GHSR and ERK were analyzed by western blotting. ALP activity,
Runx2 mRNA levels and calcium deposition were also measured.
Our data confirmed that expression of the GHSR protein is
blocked significantly by siRNA; interestingly, silencing of GHSR
also significantly inhibited ERK phosphorylation and abolished
the inhibition of ALP activity, Runx2 mRNA production and
calcium deposition stimulated by 10
–6 mol/L ghrelin. ERK
inhibitor reversed the decrease of ALP activity, Runx2 mRNA
production, and calcium deposition mediated by ghrelin, which
indicated that the phosphorylation of ERK was involved in ghrelin
signaling. Details are shown in Figure 4.
Discussion
Vascular calcification, which includes coronary and aortic
calcification, is an important risk factor for cardiovascular
morbidity and mortality [2]. Clarification of the definite
mechanisms for vascular calcification and development of effective
therapeutic strategies are both challenging areas of research.
Previous studies by our group have shown that the administra-
tion of apelin, taurine, omentin and adiponectin attenuated the
calcification of CVSMCs [23–25]. At present, two universally
accepted cell models are used to study osteoblastic differentiation
of VSMCs in vitro. In the first model, VSMCs are induced by beta-
GP [19,26,27]. In the second, around 20–30% VSMCs undergo
and form calcified matrix spontaneously in vitro without a
phosphate donor in the medium, which is called CVSMCs and
have been used to investigate osteoblastic differentiation mecha-
nism in our and other’s previous studies [22–25,28]. This cell
model produces cells that have a more typical osteoblast
phenotype, as cells can express ALP, osteocalcin, Runx2, and
automatically form calcified matrix nodules. In addition, these
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e33126Figure 1. Effects of ghrelin on alkaline phosphatase (ALP) activity, Runx2 protein expression, bone morphogenetic protein-2 (BMP-
2) mRNA expression and calcium deposition in calcifying vascular smooth muscle cells (CVSMCs). (A) Effect of ghrelin on ALP activity.
The cells were cultured with or without 1026 mol/L ghrelin for the indicated time periods. ALP activity was measured by an ALP kit, normalized to
the cellular protein contents, and presented as mean 6standard deviation (SD) (n=3). (B, C) Effect of ghrelin on Runx2 expression. The cells were
cultured for 48 h with or without 1026 mol/L ghrelin and presented as mean 6SD (n=3). The expression of Runx2 was measured by western
blotting. (D) Effect of ghrelin on BMP-2 mRNA expression. The cells were cultured with or without 1026 mol/L ghrelin for the indicated time periods.
BMP-2 mRNA expression was determined by real-time quantitative polymerase chain reaction (qPCR). Results are expressed as fold of control. Bars
present mean 6SD (n=3). (E) A representative entire plate view of the Alizarin Red S staining in 24-well plates for control cells and cells treated with
ghrelin in 12-day cultures. (F) Effect of ghrelin on calcium deposition. The cells were cultured for 12 days with or without 1026 mol/L ghrelin and
presented as mean 6SD (n=3). The calcium contents of the cell layers were measured by the atomic absorption spectroscopy method.
doi:10.1371/journal.pone.0033126.g001
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than do beta-GP-induced VSMCs as demonstrated in previous
studies [28,29] and in the present work. Therefore, we decided to
use a maximum 72 h period for CVSMCs and up to 9 days for
beta-GP-induced VSMCs to examine the osteoblastic differenti-
ation of these cells.
Figure 2. Effects of ghrelin on alkaline phosphatase (ALP) activity, Runx2 protein expression, bone morphogenetic protein-2 (BMP-
2) mRNA expression and calcium deposition in vascular smooth muscle cells (VSMCs) cultured with beta-GP. (A) Effect of ghrelin on
ALP activity. The cells were cultured with or without 1026 mol/L ghrelin for the indicated time periods. ALP activity was measured by an ALP kit,
normalized to the cellular protein contents, and presented as mean 6 standard deviation (SD) (n 3). (B, C) Effect of ghrelin on Runx2 expression. The
cells were cultured for 6 days with or without 1026 mol/L ghrelin above and presented as mean 6SD (n=3). The expression of Runx2 was measured
by western blot. (D) Effect of ghrelin on BMP-2 mRNA expression. The cells were cultured with or without 1026 mol/L ghrelin for the indicated time
periods. BMP-2 mRNA expression was determined by real-time quantitative polymerase chain reaction (qPCR). Results are expressed as fold of
control. Bars represent mean 6standard deviation (SD) (n=3). (E) Effect of ghrelin on calcium deposition. The cells were cultured for 20 days with or
without 1026 mol/L ghrelin and presented as mean 6SD (n=3). The calcium contents of the cell layers were measured by the atomic absorption
spectroscopy method.
doi:10.1371/journal.pone.0033126.g002
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different lengths of time and important phenotypic markers of
osteoblastic differentiation were detected. A previous study
observed that 1028–1026 mol/L ghrelin treatment for 10 days
decreased the ALP activity of calcified VSMCs in a dose-
dependent manner [19]; here we demonstrated that the decrease
of ALP activity by ghrelin also may be time dependent. Our data
showed that treatment of CVSMCs with 1026 mol/L of ghrelin
inhibited ALP activity from 24 h up to 72 h, the most significant
inhibition of ALP activity occurred at 48 h. Furthermore,
incubation with 1026 mol/L of ghrelin for 3 days inhibited the
ALP activity of VSMCs induced by beta-GP. It has been shown
previously that Runx2 suppresses myocardin-induced smooth
muscle cell (SMC) phenotype genes and concomitantly promotes
osteogenic conversion of SMCs [30]. Nakahara et al. [31]
demonstrated that fibroblast growth factor 2 (FGF-2) induction
of osteoblast-marker gene expression was mediated by an increase
in DNA-binding activity of Runx2. Recently, Byon et al. [29] have
reported that Runx2 promoted the osteoblastic differentiation of
macrophages by up-regulating the expression of receptor activator
of nuclear factor kappa B ligand (RANKL), which mediates the
crosstalk between CVSMCs and migration and differentiation of
macrophages into osteoclast-like cells in the atherosclerotic lesions.
Taken together, these results support the proposal that Runx2 may
be a key regulatory factor in vascular calcification. It has been
reported that treatment with 1027 mol/L ghrelin for 7 days
significantly suppressed the expression of Runx2 in preosteoblast
C3H10T1/2 cells, while another independent experiment showed
that ghrelin did not affect the expression of Runx2 in the
differentiation of rat osteoblasts [18,32]. Our results demonstrated
that the expression of Runx2, an important transcription factor for
osteoblastic differentiation, and calcium deposition are both down-
regulated significantly by ghrelin. The effects of ghrelin may be
tissue or cell specific. BMP-2 is expressed in VSMCs and can
induce the expression of Runx2 in the process of osteoblastic
differentiation of VSMCs [22]. Our quantitative real-time PCR
data showed that BMP-2 mRNA expression is significantly down-
regulated by ghrelin in CVSMCs and VSMCs induced by beta-
GP. Furthermore, the effect was time dependent. Taking together
the previous studies and the present results, we think that ghrelin
may affect osteoblastic differentiation of VSMCs in both a dose-
and time-dependent manner. It has been demonstrated by our
group that treatment with apelin for 48 h decreased the ALP
activity of CVSMCs significantly and inhibited osteoblastic
differentiation of CVSMCs, accompanied by suppression of
Runx2 expression [23]. Our present experiment demonstrated
that ghrelin, which might act in a similar manner to apelin,
inhibited osteoblastic differentiation of VSMCs.
To gain further insight into the mechanism by which ghrelin
inhibits osteoblastic differentiation of CVSMCs, we evaluated
signaling pathway events. The MAPKs, including ERK, JNK and
p38, are serine/threonine kinases that are involved mainly in the
activation of nuclear transcription factors that control cell
proliferation, differentiation and apoptosis [23,33]. Several
previous studies have shown that ERK is involved in osteoblastic
differentiation and mineralization of VSMCs, but this involvement
is still controversial. Radcliff et al. [28] suggested that IGF-I
inhibited osteoblastic differentiation and vascular-cell mineraliza-
tion via both the ERK and PI3K pathways. Liu et al. [20]
reported that selenite suppressed H2O2-enhanced osteoblastic
differentiation and calcification of VSMCs through the ERK
pathway. Shi et al. [26] found that LaCl3 suppressed the beta-GP-
induced osteoblastic differentiation and calcification of rat VSMCs
by the activation of both ERK and JNK MAPK pathways.
However, Ding et al. [27] demonstrated that fibronectin enhanced
osteoblastic differentiation of VSMCs via the ERK signaling
pathway. Our present study suggested that ghrelin inhibited
osteoblastic differentiation and mineralization of CVSMCs via the
ERK signaling pathway, a finding that is in accordance with
Radcliff’s, Liu’s, and Shi’s work and our previous studies [4,5,23].
However, we found no activation of the other kinases JNK and
p38 in this experiment. Our data showed that 1029 mol/L of
ghrelin had no stimulus effect on ERK activation, but that a dose
of 1028t o1 0 26 mol/L of ghrelin stimulated the expression of p-
ERK, and therefore that the stimulus is dose dependent.
Furthermore, both silencing of GHSR and blockade of ERK
suppressed the inhibition of ghrelin on ALP activity, Runx2
mRNA expression and calcium content. Overall, our study
suggested that the ghrelin/GHSR signaling pathway may
attenuate osteoblastic differentiation of CVSMCs through an
ERK-dependent pathway.
In summary, our study identified the effects of ghrelin on
osteoblastic differentiation of VSMCs and demonstrated that
Figure 3. Effects of ghrelin on mitogen-activated protein
kinase (MAPK) activation in calcifying vascular smooth muscle
cells (CVSMCs). (A, B) Cells were exposed to 1026 mol/L ghrelin for
0–60 min, or 50 mM hydrogen peroxide (H2O2) for 15 min as a positive
control for p38 and JNK activation. Cell lysates were subjected to
western blotting and incubated with antibodies against p-ERK, ERK, p-
p38, p38, p-JNK, and JNK. The representative results are shown. (C) Cells
exposed to 1029 mol/L, 10
28 mol/L, 10
27 mol/L, and 10
26 mol/L of
ghrelin for 30 min. Cell lysates were subjected to western blotting and
incubated with antibody against p-ERK and ERK. The representative
results are shown.
doi:10.1371/journal.pone.0033126.g003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e33126Figure 4. ERK signaling pathway mediated the inhibitory effect of ghrelin on osteoblastic differentiation of calcifying vascular
smooth muscle cells (CVSMCs). (A) The expression and silencing of growth hormone secretagog receptor (GHSR) on CVSMCs. Cells were
incubated with scramble siRNA or GHSR siRNA for 72 h. Total cellular protein was subjected to western blot analysis using anti-GHSR antibody. The
anti-GHSR antibody identified a band at 44 kDa. b-actin was used as the control. (B) The activation of extracellular signal-related kinase (ERK) under
the silencing of GHSR. Cells were incubated with scramble siRNA or GHSR siRNA for 72 h prior to treatment with 1026 mol/L ghrelin for 30 min. Total
proteins were subjected to western blotting and incubated with antibody against p-ERK and ERK. The representative results are shown. (C) The
activation of ERK under PD98059. Cells were incubated with PD98059 (10 mM) for 2 h prior to treatment with 1026 mol/L of ghrelin for 30 min. Total
proteins were subjected to western blotting and incubated with antibody against p-ERK and ERK. The representative results are shown. (D, E, F) The
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e33126ghrelin exerted this suppression by promotion of the phosphor-
ylation of ERK. Our findings suggested that ghrelin may be a
prospective target for vascular calcification therapy. However,
further study is necessary before any clinical application is
considered.
Materials and Methods
Reagents
Synthetic mouse ghrelin peptide (Gly-Ser-Ser (n-octanoyl)-Phe-
Leu-Ser-Pro-Glu -His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-
Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg) was purchased from
the Chinese Peptide Company (Hangzhou, China). Anti-mouse
Runx2 antibody, anti-mouse monoclonal IgG peroxidase conju-
gate antibody, anti-b-actin polyclonal antibody, anti-ERK, p-
ERK, p-p38, p38, JNK, p-JNK antibodies, and anti-mouse GHSR
antibody were purchased from Santa Cruz Biotechnology Inc
(Waltham, MA, USA). ERK inhibitor PD98059 was purchased
from Calbiochem Corp. (San Diego, CA, USA). The ALP assay kit
was purchased from Nanjing Jiancheng Bioengineering Institute
(Nanjing, China). Mouse GHSR siRNA was purchased from
GenePharma Company (Shanghai, China).
Cell culture and in vitro calcification
Mouse VSMCs were acquired by an explant method as our
previous described [23,25], and after approved by the Ethics
Committee of the Second Xiangya Hospital of Central South
University, China. Briefly, the tunica media was isolated from the
mouse aortas. The tissue was fragmented (1–2 mm3), the aortas
were minced and digested in 5 ml of digestion solution (0.125 mg/
ml elastase, 0.25 mg/ml soybean trypsin inhibitor, 10 mg/ml
collagenase I, 2.0 mg/ml crystallized bovine albumin, and 15 mM
HEPES) at 37uC for 45 min. The cellular digests were filtered
through sterile 100-mMnylon mesh, centrifuged at 1,000 rpm for
10 min, and washed twice in Dulbecco’s Modified Eagle’s medium
(DMEM) containing 10% FBS (Gibico-BRL Corp., NY, USA)
before culture in the same medium. CVSMCs were isolated from
cultures in which multicellular nodules spontaneously appeared.
From these nodule-forming cultures, cells were cloned by limiting
dilution and single cell harvesting. Colonial lines were identified as
CVSMCs by their positive staining with monoclonal antibody a-
actin and by their ability to express high levels of ALP and form
calcified nodules. Immunocytochemical examination showed
positive staining in all cells for a-smooth muscle actin [23].
CVSMCs were seeded in DMEM containing 4.5 g/L of glucose,
10% FBS and 10 mM sodium pyruvate and the medium was
refreshed every 2 days. VSMCs induced by beta-GP were cultured
in above mentioned medium including 10 mM beta-GP. We used
1029 mol/L to 1026 mol/L of ghrelin to incubate VSMCs in
the following experiment. The dose of ghrelin was selected based
on the previous research [19]. After incubation, the following
measurements were performed.
Analysis of ALP activity
Cells were cultured in the absence or presence of 1026 mol/L
ghrelin, and washed three times with PBS. The cell layers were
scraped into a solution containing 20 mM Tris–HCl, pH 8.0, and
150 mM NaCl, 1% Triton X-100, 0.02% NaN3 and 1 mM
PMSF. After the lysates were homogenized by sonication for 20 s,
the ALP activity was measured using an ALP kit.
Measurement of mineralized matrix formation
For Alizarin Red S staining, CVSMCs in 24-well plates were
cultured in medium that contained either 1026 mol/L ghrelin or
vehicle for 12 days. Then, the extent of mineralized matrix was
determined by Alizarin Red S staining [34]. Briefly, cells were
fixed in 70% ethanol for 1 h at room temperature and stained with
40 mM Alizarin Red S for 10 min. Next, cell preparations were
washed with PBS to eliminate nonspecific staining.
For the quantification of calcium levels, cells were washed with
PBS and decalcified with 0.6 N HCl for 24 h, Calcium content
was determined by measuring the concentrations of calcium in the
HCl supernatant by atomic absorption spectroscopy. After
decalcification, the cells were washed three times with PBS and
the cells were solubilized with 0.1 N NaOH/0.1% SDS. The
protein content was measured with a BCA protein assay. The
calcium content of the cell layer was normalized to the protein
content.
Silence of GHSR by RNA interference
RNA interference was used to silence the expression of GHSR
in CVSMCs. GHSR-siRNA and scramble siRNA were synthe-
sized by GenePharma Biotechnology (Shanghai, China).
CVSMCs were plated in six-well plates and cultured for 24 h in
medium without antibiotics. Cells were transfected with siRNAs
(100 pmol/well) using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. Cells were cultured for 72 h.
To detect calcium deposition 6 days after transfection, a second
siRNA transfection was performed 72 h after the first time siRNA
transfection as previously described [35,36]. The efficiency of
siRNA was determined by protein analysis.
Western blot analysis
Total protein extracts of cultured cell were prepared with RIPA
lysate (Beyotime, China) and equal amounts of protein were
submitted to SDS-PAGE and transferred onto 0.2 mm PVDF
membranes (Pall, USA) to be stained with appropriate antibodies
(anti-p-p38, -p38, -p-ERK, -ERK, -p-JNK, -JNK, -Runx2, -
GHSR and b-actin antibodies). The reaction was visualized with
chemiluminescence.
Real-time quantitative PCR assay for Runx2 and BMP
mRNA expression
Total RNA was extracted by TRIzol (Invitrogen), and then
cDNA was prepared with a RevertAid First Strand cDNA
Synthesis Kit (Fermentas). The PCR was performed with Maxima
SYBR Green/Rox qPCR Master Mix (Fermentas). All the
procedures were strictly performed as per instructions. Amplifica-
tion and detection were performed as follows: 50uC for 2 min,
95uC for 10 min and then 40 cycles of 95uC for 15 s, 60uC for
30 s, and 72uC for 30 s. A total 20 ml of reaction system consists of
SYBR Mix 10 ml, Rnase-free water 7 ml, 1 ml/0.3 mmol/l
forward/reverse primer and 1 ml/500 ng cDNA template. The
results of real-time quantitative PCR were automatically analyzed
by the Roche Light-Cycler technology. GAPDH was used as the
decreased alkaline phosphatase (ALP) activity, Runx2 mRNA, and calcium deposition mediated by the GHSR/ERK pathway. Cells were incubated with
PD98059 (10 mM) for 2 h prior to treatment with 1026 mol/L of ghrelin. Cells were also treated with the scramble siRNA or GHSR siRNA in the
presence of 1026 mol/L of ghrelin. ALP activity, Rnux2 mRNA, and calcium deposition were measured. The bars represent the mean 6standard
deviation (SD) (n=3).
doi:10.1371/journal.pone.0033126.g004
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were as follows: Runx2 sense: 59-CCGGTCTCCTTCCAGGAT-39,
anti-sense: 59-GGGAACTGCTGTGGCTTC-39;B M P - 2s e n s e :5 9-
AGCTGCAAGAGACACCCTTT-39, anti-sense: 59-CATGCCT-
TAGGGATTTTGGA-39;GA P D Hs e n s e :5 9-GGCTGCCCAGAA-
CATCAT-39, anti-sense: 59-CGGACACATTGGGGGTAG-39.
Statistical analysis
Results were presented as means 6 SD, and analysis was
performed with Statistical Product and Service Solutions (ver-
sion 13.0). Differences between groups were evaluated by one-way
analysis of variance (ANOVA). The data shown were based on
three independent experiments. A level of p,0.05 was considered
significant.
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